We independently selected these deals and products because we love them, and we think you might like them at these prices. E!

Lilly Pulitzer on Oct. 1 launched its annual Print with a Purpose collection with the Breast Cancer Research Foundation, the company announced in a news release. As part of the campaign ...

ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its second quarter of fiscal 2024 ended August 3, 2024. Consolidated net sales ...

Sham Gad is a seasoned and well-respected financial journalist, whose stories have been published in multiple high-profile online publications. His diverse areas of coverage include credit rating ...

Pharmaceutical giant Eli Lilly (LLY) is putting $4.5 billion toward building a new site to develop and manufacture drugs. The Lilly Medicine Foundry, located in Lebanon, Indiana, is a first-of-its ...

Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.

Eli Lilly has finally made enough supply of its popular medicine tirzepatide to meet soaring demand, which should help the company widen its share of the booming weight-loss drug market.

Jason Shams is an American–Iranian who has spent most of his life in Iran. He has worked as translator, interpreter, journalist, and political analyst in Iran for more than twenty years.